SCHEMBL30983947

SCHEMBL30983947

CC(C)(C)OC(=O)N1CCN(CCOc2ccc(-c3nc4c(Cl)ncnc4n3Cc3cccc(Cl)c3)c(Cl)c2)CC1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 1/20 0.45
▸ CNR1 P21554 3/20 0.44
▸ CNR2 P34972 2/20 0.44
▸ GPR4 P46093 1/20 0.43
▸ EPHX2 P34913 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ MAPK1 P28482 2/20 0.38
▸ DRD3 P35462 1/20 0.38
▸ GPR119 Q8TDV5 2/20 0.37
▸ AURKA O14965 1/20 0.37
▸ RPS6KB1 P23443 1/20 0.37
▸ TBK1 Q9UHD2 2/20 0.36
▸ LMNA P02545 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ SQOR Q9Y6N5 1/20 0.36
▸ SLC6A2 P23975 1/20 0.36
▸ SLC6A4 P31645 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30983846 0.94 CNR1 (0.47) ADORA2ACNR1CNR2GPR4EPHX2
SCHEMBL30984030 0.90 PIK3CD (0.45) ADORA2ACNR1CNR2
SCHEMBL30983875 0.90 CNR1 (0.41) ADORA2ACNR1CNR2GPR4EPHX2
SCHEMBL30983946 0.90 CNR1 (0.44) ADORA2ACNR1CNR2GPR4EPHX2
SCHEMBL30983922 0.87 CNR1 (0.39) ADORA2ACNR1CNR2GPR4EPHX2
SCHEMBL30984010 0.86 CNR1 (0.43) ADORA2ACNR1CNR2GPR4EPHX2
SCHEMBL30984027 0.84 CNR1 (0.42) CNR1CNR2GPR4EPHX2DRD3
SCHEMBL30983802 0.84 CNR1 (0.43) CNR1CNR2GPR4EPHX2DRD3
SCHEMBL30984074 0.82 CNR1 (0.42) CNR1CNR2GPR4EPHX2DRD3
SCHEMBL30983785 0.82 CNR1 (0.41) CNR1CNR2GPR4EPHX2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed
Send feedback